In a prospective, randomized, double-blind trial, 149 patients with advanced human immunodeficiency virus (HIV) infection were randomized to receive itraconazole capsules (200 mg daily) and 146 to receive a matched placebo. Both groups were monitored for evidence of fungal infections. Baseline characteristics of the two groups were similar. Failure of prophylaxis occurred in 29 (19%) of the itraconazole recipients and 42 (29%) of the placebo recipients (P Å .004; log-rank test). There were 6 invasive fungal infections in the itraconazole group (4, histoplasmosis; 1, cryptococcosis; 1, aspergillosis) and 19 in the placebo group (10, histoplasmosis; 8, cryptococcosis; 1, aspergillosis) (P Å .0007; log-rank test). Itraconazole significantly delayed time to onset of histoplasmosis (P Å .03; log-rank test) and cryptococcosis (P Å .0005; log-rank test). Prophylaxis failure due to recurrent or refractory mucosal candidiasis occurred with similar frequency in the two groups (itraconazole, 15%; placebo, 16%). A survival benefit was not demonstrated. Itraconazole generally was well tolerated. Primary prophylaxis with itraconazole capsules prevents histoplasmosis and cryptococcosis in patients with HIV infection.
HIV infection living in cities with high rates of endemic histo- resided in an area with endemic histoplasmosis. Secondary objectives were to assess the safety and efficacy of itraconazole
The study endpoints included (1) toxicity necessitating disin the prevention of other fungal infections and to assess the continuation of study medication and (2) failure of prophylaxis, impact of prophylaxis on in vitro susceptibility of selected defined as development of histoplasmosis, cryptococcosis, asfungal pathogens to itraconazole and fluconazole. pergillosis, or other proven or probable systemic fungal infec-Subjects were eligible for participation if they met the followtion; oropharyngeal or vaginal candidiasis requiring ú2 weeks ing criteria: age of §13 years; HIV infection, documented by of treatment with a systemically active antifungal drug or repositive enzyme immunoassay and western blot tests; life expecquiring such treatment on more than one occasion; or esophatancy of §1 year; no life-threatening infection or malignancy geal candidiasis requiring ú3 weeks of treatment with a sysother than cutaneous Kaposi's sarcoma; absolute CD4 lymphotemically active antifungal drug or more than one course of cyte count õ150/mm 3 within 1 year prior to study enrollment; treatment. and residence in a city with a high prevalence of histoplasmosis.
Confirmed histoplasmosis was defined as a compatible clini-Exclusion criteria included the following: use of an investigacal syndrome consistent with signs and symptoms of pulmotional drug concurrently or within 1 month prior to initiation of nary or disseminated fungal infection, along with either a posithe study (with the exception of drugs available under a U.S. Food tive culture for H. capsulatum or a histopathologically positive and Drug Administration-authorized expanded-access program); tissue biopsy specimen or buffy coat smear. Probable histoplaspregnancy, lactation, or (among women) failure to use a medimosis was defined as a compatible clinical syndrome and both cally approved and effective method of contraception; history of detection of Histoplasma polysaccharide antigen in body fluids intolerance of imidazole or triazole compounds; inability to take and initiation of specific antifungal treatment, unless further oral medications; history of active histoplasmosis; active fungal evaluation identified a nonfungal pathogen or cause. Other funinfection (cryptococcosis, aspergillosis, coccidioidomycosis, or gal infections were classified as confirmed or probable on the oropharyngeal, vaginal, esophageal, or disseminated candidiasis); basis of previously established criteria [11] . use of a medication with a known interaction with itraconazole; and elevated liver function test values (ú5.0 times the upper limit of normal for aspartate aminotransferase, alanine amino-Laboratory Tests transferase, or alkaline phosphatase or ú2.5 mg/dL for total Serum specimens were obtained at baseline, every 6 months, bilirubin). and when breakthrough fungal infections were suspected, and Subjects were randomized in a 1:1 ratio to take either two these were frozen at 070ЊC. Specimens were obtained at ran-100-mg itraconazole capsules once daily or two placebo capdom times following itraconazole dosings. After completion of sules, which were identical in appearance to the itraconazole the study, itraconazole concentrations in banked serum specicapsules. Randomization was stratified by site, and each site mens were measured by bioassay, with use of a method modihad an independent randomization code. Study medication fied from a procedure by Bodet et al. [15] , at the Histoplasmosis could not be taken within 2 hours before or after a dideoxyino-Reference Laboratory. Samples were tested in duplicate, and sine dose, because dideoxyinosine impairs absorption of itracoconcentrations were calculated by comparison to a standard nazole [14] . Clinical and laboratory assessments were undercurve ranging from 0.62 mg/mL to 20.0 mg/mL [15] . Culture taken at baseline, 6 weeks, 3 months, and then every 3 months specimens were obtained from patients who had clinical evifor the remainder of the study. At baseline, a histoplasmin skin dence of mucosal or systemic fungal infections and were protest (Parke-Davis, Morris Plains, NJ) was performed and CF cessed at local hospital laboratories. Isolates were subcultured titers of antibody to Histoplasma yeast and mycelial antigens once, and the freshly grown cultures were suspended in lactase were measured at the Histoplasmosis Reference Laboratory glycerol freezing medium and stored frozen in liquid nitrogen. (Indianapolis), with use of commercially available reagents H. capsulatum isolates were evaluated in vitro for susceptibility and standardized methods. Under the following circumstances, to itraconazole and fluconazole with use of a macrobroth study medication was discontinued but subjects continued to be method slightly modified from the M27-T method of the Naevaluated for outcome: the need for extended use of disallowed tional Committee for Clinical Laboratory Standards (NCCLS) medications; onset of pregnancy during the study; and grade [16] . The MIC was defined as the concentration of drug re-3 or 4 toxicity that mandated withdrawal of the study drug.
quired to inhibit 80% of the organism's growth, as detailed in During the course of the study, administration of a systemithe NCCLS methodology [16] . cally active antifungal drug for up to 2 weeks was allowed under the following circumstances: for oropharyngeal candidiasis nonresponsive to topical therapy, for vaginal candidiasis Statistical Considerations nonresponsive to topical therapy; and as empirical therapy for a suspected systemic fungal infection. A 3-week treatment course
The study hypothesis was that itraconazole would reduce the annual incidence of histoplasmosis from 15% to 5% or less was allowed for esophageal candidiasis.
/ 9c65$$my15
04-06-99 07:57:59 cidas UC: CID by an exponential distribution, we calculated the sample size to be 220 patients, with 110 in each arm of the study [17] . On Prophylaxis failure 29 (19.5)* 42 (28.8) the basis of an anticipated dropout rate of Ç20% in each treat-Histoplasmosis 4 (2.7) † 10 (6.8) ment group, it was estimated that 130 patients should be ac-
crued in each arm, for a total enrollment of 260 patients.
Oropharyngeal candidiasis
All analyses were performed on an intention-to-treat basis.
(recurrent or refractory) 17 [19] . The Cox proportional hazards model was not utilized Two hundred ninety-eight patients were enrolled, of whom to investigate concomitant factors related to development of 3 were ineligible (2 withdrew consent before receiving study systemic mycoses because of an insufficient number of meanmedication, and 1 was taking disallowed medications and never ingful clinical events. Interim analyses were reviewed by an received study drug) and 295 were evaluable. The data-safety independent data-safety monitoring board and maintained an monitoring board requested that enrollment exceed the origioverall type 1 error of 0.05.
nally planned sample size because of a lower than anticipated incidence of invasive fungal infections during the early phase of the study. Among evaluable cases, 146 were randomized to the placebo arm and 149 to the itraconazole arm. Baseline of cryptococcosis were confirmed (7 of 8 in the placebo group and the single case in the itraconazole group). Both cases of aspergillosis were confirmed. Thirty-nine of 46 cases of mucosal candidiasis (11 of 14 esophageal and 28 of 32 oropharyngeal) also were confirmed. Only 1 of the 4 itraconazole recipients who developed histoplasmosis was taking study medication at the time of diagnosis; among the other 3 subjects, 2 discontinued the itraconazole therapy because of adverse events (skin rash; headache and dizziness) and a third required a disallowed medication, necessitating discontinuation of study medication. The one itraconazole recipient who developed cryptococcosis discontinued study medication 4 weeks prior to diagnosis because of a skin rash. The itraconazole recipient who developed aspergillosis was taking study medication when the infection occurred. Thus, there were only two patients who were taking itraconazole at the time of onset of systemic fungal infection. One of 6 itraconazole recipients who developed recurrent or refractory esophageal candidiasis was receiving study medication when the prophylaxis failure occurred, and 10 of 17 itraconazole recipients who had recurrent oropharyngeal candidiasis were taking study medication at the time of diagnosis.
In total, 93 (63.7%) of 146 patients in the placebo arm, vs. 91 (61.1%) of the 149 in the itraconazole arm, were still taking study medication at the time of either prophylaxis failure or conclusion of the protocol. If only those patients who continued with the assigned treatment are considered, prophylaxis failure occurred in 28 (30%) of 93 placebo recipients and in 13 (14%) of 91 itraconazole recipients when they completed the study study for 128 (once for 114 and twice or more for 14). The median itraconazole concentration was 1.07 mg/mL (range, 0 -32.6 mg/mL), and the mean ({SE) level was 2.86 { 0.39 mg/mL. Fifty-one levels (39.8%) were undetectable, 12 (9.4%) Itraconazole significantly delayed time to onset of histoplasmosis (P Å .031; log-rank test) (figure 1), cryptococcosis were between zero and 1 mg/mL, and 65 (50.8%) were ú1 mg/mL. Among the 14 patients who had multiple concentra-(P Å .0005; log-rank test) (figure 1), and all systemic fungal infections (P Å .0007; log-rank test). At least one episode tions measured, at least one concentration was undetectable in 12 cases; however, 8 of these 12 patients had detectable of mucosal candidiasis occurred in 74 (51%) of the patients randomized to receive placebo and in 51 (34%) of those who concentrations on other occasions. The benefit of itraconazole prophylaxis was seen only in the received itraconazole (P Å .004; x 2 test). Twenty-three itraconazole recipients' prophylaxis failed because they had 2 or subset of patients with lower baseline CD4 lymphocyte counts. Among patients with CD4 lymphocyte counts ú100/mm 3 , itra-more episodes of mucosal candidiasis (17, oropharyngeal; 6, esophageal) requiring systemic antifungal therapy; likewise, 23 conazole did not significantly decrease the incidence of histoplasmosis (P Å .46; log-rank test) or any other fungal infections placebo recipients' regimens failed for the same reason (15 had oropharyngeal candidiasis and 8 had esophageal candidiasis) (P Å .71; log-rank test). Forty-three placebo recipients had baseline CD4 counts ú100/mm 3 . Three cases of histoplasmosis (P Å .27; x 2 test). There were no prophylaxis failures due to vaginal candidiasis.
(7.0%) and one case of cryptococcosis (2.3%) occurred in this group. Among the 48 patients with CD4 lymphocyte counts Among 25 invasive fungal infections, 22 were confirmed and 3 were considered probable. Twelve of 14 cases of histo-ú100/mm 3 randomized to receive itraconazole, there were two cases of histoplasmosis (4.2%) and one case of cryptococcosis plasmosis were confirmed, including all 4 cases in the itraconazole arm and 8 of 10 in the placebo arm. Eight of the 9 cases (2.1%). In the subset with counts õ100/mm 3 , itraconazole pro-/ 9c65$$my15 04-06-99 07:57:59 cidas UC: CID receiving combination antiretroviral therapy at the completion of the study. Among the 14 patients who developed histoplasmosis, only phylaxis significantly decreased the incidence of histoplasmosis 1 (7%) had a reactive histoplasmin skin test at baseline, and 6 (P Å .02; log-rank test) and all invasive fungal infections (2%) of 277 who did not acquire histoplasmosis had reactive (P Å .0009; log-rank test). Seven (7.0%) of the 103 placebo skin tests (P Å .24; x 2 test). CF antibodies to Histoplasma recipients with CD4 lymphocyte counts õ100/mm 3 developed yeast or mycelial antigens (at a titer of §1:8) were present at histoplasmosis, 7 (7.0%) developed cryptococcosis, and 1 baseline in 3 (21%) of 14 patients who developed histoplasmo-(1.0%) developed aspergillosis. Histoplasmosis occurred in 2 sis and in 37 (20%) of 185 who did not (P Å .37; x 2 test). (2.0%) of the 101 itraconazole recipients with CD4 lymphocyte Among 46 patients whose prophylaxis failed because of recurcounts õ100/mm 3 and aspergillosis occurred in 1 (1.0%); there rent or refractory oropharyngeal or esophageal candidiasis, the were no cases of cryptococcosis in this group. median baseline CD4 lymphocyte count was 42/mm 3 (range, 0-151/mm 3 ), compared with 63/mm 3 (range, 0-162/mm 3 ) among 249 whose prophylaxis did not fail (P Å .05; Wilcoxon's test).
Survival
At initiation of the study, similar proportions of patients in the Thirty-two patients (21.5%) in the itraconazole arm died, vs.
2 groups were receiving §2 antiretroviral drugs, but at study 21 (14.4%) in the placebo arm (P Å .72, log-rank test). There completion 4 (9%) of 46 patients whose prophylaxis failed, vs. were 3 deaths due to fungal infection, including those of 2 58 (23%) of 249 successfully treated patients, were receiving patients with cryptococcosis (1 in the placebo arm and 1 in combination antiretroviral therapy (P Å .03; Wilcoxon's test). the itraconazole arm; the latter patient had not taken study Median serum itraconazole concentrations were 1.4 mg/mL medication for 4 weeks prior to death) and 1 with histoplasmo-(range, 0-32.6 mg/mL) and 1.065 mg/mL (range, 0-20.5 mg/mL) sis (who was in the itraconazole arm of the study).
in the mucosal candidiasis prophylaxis-failure and prophylaxissuccess groups, respectively (P Å .94; Wilcoxon's test). Further analyses of the Candida species isolated and their susceptibilities Adverse Events to azole antifungal agents are under way [20] . Adverse events that were possibly attributed to protocol ther-Only two H. capsulatum isolates from patients whose itracoapy are reviewed in table 3. Protocol therapy was discontinued nazole prophylaxis failed were available for analysis; for neidue to presumed adverse events in 18 cases, 5 in the placebo ther of these isolates were the MICs of itraconazole or fluconagroup (3.4%) and 13 in the itraconazole group (8.7%) zole significantly higher than for those of the three available (P Å .04; x 2 test). Skin rash occurred more frequently in pa-H. capsulatum isolates from placebo recipients. For both isotients who received itraconazole (P Å .02; x 2 test) and was lates from itraconazole recipients, the MIC of itraconazole was the reason for discontinuation of protocol therapy for six of 0.0025 mg/mL and the MIC of fluconazole was 1.0 mg/mL. 13 itraconazole recipients. There were two cases of Stevens-
The MICs for the three isolates from subjects who received Johnson syndrome among itraconazole recipients, although one placebo were 0.0025, 0.0025, and 0.005 mg/mL of itraconazole of these patients also was receiving trimethoprim-sulfamethoxand 1.0, 1.0, and 2.0 mg/mL of fluconazole. azole, which may have been the cause of this disorder. Gastro-Discussion intestinal toxicities were reported by a large number of subjects but were relatively evenly distributed between the two regi-Our results show that primary prophylaxis with itraconazole capsules is effective in the prevention of histoplasmosis and mens. cryptococcosis. Although four patients in the itraconazole in a nonblinded fashion in the ACTG study [11] , itraconazole was compared with a blinded placebo in the current study. This group developed histoplasmosis, only one was still taking the medication at the time the infection occurred. Similarly, the difference may have had an impact on the voluntary discontinuation rates in the two clinical trials. During the period this one patient in this group who developed cryptococcosis had stopped taking the drug 1 month prior to the onset of infection. study was conducted, use of chronic suppressive therapy with fluconazole for mucosal candidiasis was a widespread practice, Itraconazole was more effective in the prevention of systemic mycoses than noted in prior studies with fluconazole [9, 11] . so physicians may have been more likely to discontinue prophylaxis and initiate fluconazole therapy for oropharyngeal or A prospective placebo-controlled study of daily fluconazole prophylaxis demonstrated a significant reduction in incidence esophageal candidiasis. The disparity between the efficacy of itraconazole for pre-of cryptococcosis, especially among patients with CD4 lymphocyte counts õ50/mm 3 [11] . Fluconazole prophylaxis also vention of histoplasmosis and cryptococcosis and its relative lack of efficacy for prevention of recurrent mucosal candidiasis was associated with decreased incidence of cryptococcosis in a prospective uncontrolled study [9] , in a prospective trial with may be related to differences in drug concentrations at the sites of infection. Concentrations of itraconazole in blood and lung historical controls [10] , and in a case-control study [21] . However, fluconazole prophylaxis was not associated with a reduc-may be most important in preventing acquisition of infection with C. neoformans and H. capsulatum, whereas candidiasis tion in the incidence of histoplasmosis in these studies [10, 11] . Only the current trial was designed primarily to assess is almost always a mucosal infection in patients with AIDS. Itraconazole capsules, which were utilized in our study, are prophylaxis of histoplasmosis.
In the AIDS Clinical Trials Group (ACTG) study by Pow-partially dependent on an acidic gastric pH for absorption and are variably absorbed in HIV-infected patients [25] . Develop-derly and co-workers, the incidence of systemic mycoses was reduced from 10.9% among the patients receiving clotrimazole ment of mucosal candidiasis could not be attributed to impaired drug absorption, however, since serum itraconazole concentra-to 3.3% among those receiving daily fluconazole, over a median observation period of 35 months, an overall reduction of 62% tions were comparable between the patients in the candidiasis prophylaxis-failure and prophylaxis-success groups. Mucosal [11] . In our study itraconazole reduced the incidence of systemic mycoses from 13.0% to 4.1%, a 73% reduction, over a concentrations of itraconazole may be inadequate to suppress infection, even when the drug is well absorbed. median follow-up period of 16 months. Comparison of the two studies by expression of the efficacy as numbers of cases Although high salivary concentrations of itraconazole are attained after administration of itraconazole oral solution, the prevented per 100 patient-years reveals that 2.2 cases were prevented by fluconazole, vs. 8.1 cases by itraconazole. metabolite hydroxyitraconazole is undetectable in saliva despite twofold higher plasma concentrations of hydroxyitracona-Several factors other than the choice of study drug might explain these differences. Our study was restricted to patients zole than of the parent compound [26] . This finding supports the hypothesis that the low efficacy of the capsule formulation with CD4 lymphocyte counts õ150/mm 3 , while the ACTG fluconazole study included patients with counts õ200/mm 3 ; for prevention of recurrent or refractory oropharyngeal and esophageal candidiasis was caused by inability to achieve ther-the median CD4 lymphocyte count of the group receiving itraconazole was 57/mm 3 , while that of the group receiving fluco-apeutic concentrations at the mucosal surface. Use of itraconazole oral solution, which has efficacy against mucosal candidia-nazole was 90/mm 3 . In addition, our prophylaxis study was restricted to four cities with high attack rates of histoplasmosis, sis similar to that of fluconazole [27 -29] , might be expected to reduce the incidence of recurrent candidiasis as a cause of while the ACTG fluconazole study was conducted throughout the United States. Other important considerations may be that prophylaxis failure. It is important to note that this study was conducted immedi-fluconazole is less effective than itraconazole for treatment of histoplasmosis in HIV-seronegative and HIV-seropositive ately before the era when highly active antiretroviral therapy (HAART) became available. Despite the fact that none of our patients [22, 23] and that H. capsulatum has been shown to acquire resistance to fluconazole [24] , whereas acquired resis-patients received HAART, those who were being treated with two or more antiretroviral drugs at the completion of the study tance to itraconazole has not been demonstrated.
Although itraconazole was highly effective in preventing were significantly less likely to have prophylaxis fail. Thus, even suboptimal antiretroviral therapy was associated with a histoplasmosis and cryptococcosis in our study and fewer patients who received itraconazole had documented oropharyn-reduction in the incidence of opportunistic fungal infections. In summary, our data show that itraconazole (200 mg daily) geal candidiasis, it did not reduce the incidence of recurrent or refractory oropharyngeal or esophageal candidiasis. A previous is effective primary prophylaxis for histoplasmosis and cryptococcosis in patients with advanced HIV infection and generally ACTG study showed that fluconazole prophylaxis decreased the incidence of mucosal candidiasis [11] . Differences in proto-is well tolerated. Itraconazole prophylaxis should be considered for those patients with CD4 lymphocyte counts £100/mm 3 col design may have influenced the outcome of these two clinical trials. Whereas fluconazole was compared with clotrimazole who reside in areas where there is a high incidence of histoplas-/ 9c65$$my15 04-06-99 07:57:59 cidas UC: CID
